Navigation Links
Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
Date:6/19/2013

nts with chronic pain."

Additional Study Results

  • Assessment of "Feeling High"
  • All oral doses of NKTR-181 scored similar to placebo in a Drug Effects Questionnaire (DEQ) assessing the treatment's effect on how "high" the subject felt (on a scale of 0 (not at all) to 100 (extremely)).  Oxycodone oral solution resulted in a maximum mean DEQ score of 81.
    NKTR-181 maximum mean DEQ scores were 14, 14 and 23 for 100 mg, 200 mg tablet and 400 mg, respectively, with p-values < 0.0001 as compared to oxycodone.  Placebo achieved a maximum mean DEQ score of 9. 

  • Assessment of "Sleepiness"
  • Sedation was measured using a DEQ assessment of sleepiness (on a scale of 0 (not at all) to 100 (extremely).  All doses of NKTR-181 scored lower on sleepiness when compared to oxycodone.  The maximum mean DEQ sleepiness score for oxycodone was 44 as compared to the maximum mean DEQ scores for NKTR-181 100 mg, 200 mg and 400 mg of 10, 9, and 18, respectively (p<0.0001). 

    Study DesignThe randomized, double-blind, placebo- and active-controlled, 5-way crossover trial, compared the effects of three doses of NKTR-181 oral solution (100 mg, 200 mg, and 400 mg), to the effects of 40 mg of oxycodone oral solution and placebo.  Participants were healthy adults (N=42) who were not currently physically opioid-dependent but had used opioids to attain non-medical effects on at least 10 occasions during the past year and at least once in the 12 weeks before the study.  Study participants sequentially received the five treatments, administered in a randomized, double-blinded fashion, with each treatment separated by a washout period.  The study also utilized a Williams Square cross-over design, which uses a series of randomized sequences for each individual subject.

    About NKTR-181 NKTR-181 is currently being evaluated in Phase 2 development as a twice-daily oral tablet to treat chronic
    '/>"/>

    SOURCE Nektar Therapeutics
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
    2. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
    3. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New York City
    4. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
    5. Nektar Therapeutics Reports Financial Results for the First Quarter of 2013
    6. Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
    7. Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
    8. Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
    9. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
    10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
    11. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... of Directors has approved a share repurchase program. The ... $300 million of Mallinckrodt plc ordinary shares. ... opportunities remain top priorities as we continue to pursue ...
    (Date:1/23/2015)... BOSTON , January 23, 2015 ... company, is delighted to announce that the Malcolm Campbell ... Miles Congreve (Vice President of Chemistry), Fiona Marshall ... (Chief Executive Officer and co-founder) for the seminal contributions ...
    (Date:1/22/2015)... CLEVELAND , Jan. 22, 2015  ViewRay™, a privately ... entered into an exclusive distributor agreement with ITOCHU Corporation ... radiation therapy system for the treatment of cancer in ... (me-rid-i-an) system, is the world,s first and only MRI-guided ...
    Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
    ... Texas, April 27, 2012  MetaStat, Inc. (OTCBB: MTST) ... license agreements to patent applications and technology from ... University. The first license agreement covers U.S. Patent ... Screening Test for Anti-Metastasis Treatment Efficacy"; inventors: Jeffrey ...
    ... 2012 /PRNewswire-iReach/ -- SolutionStart, Corp., a leading ... is proud to announce John Karagiannis as its new ... SolutionStart with over 12-years of strong experience in Information ... Technical Advisor, Designer, and Analyst providing comprehensive technical and ...
    Cached Medicine Technology:MetaStat, Inc. Executes Two New Licenses 2MetaStat, Inc. Executes Two New Licenses 3
    (Date:1/23/2015)... 23, 2015 Hastings and Hastings, a law ... a record number of legal representation client review requests for ... been a steady rise in the number of slip and ... home throughout the Valley. With that said, a large number ... by an experienced law firm. Hastings and Hastings is a ...
    (Date:1/22/2015)... LunaDress, with its top dressmaking technologies, has been a ... is showing its latest designs of wedding dresses and launching ... company’s CEO, all the fresh new products are designed for ... to 80% off. All the clothes from LunaDress follow up ...
    (Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in Glendale, AZ has ... (PPHA). The PPHA's passion for others' well-being and shared ... treated for obstructive sleep apnea (OSA) has propelled them into ... the valley. The most recent plans for an event will ...
    (Date:1/22/2015)... (PRWEB) January 22, 2015 Blue Cross and ... Minnesotans who exemplify what it means to “Live Fearless.” ... for people to share their stories about how they or ... simply inspired others by living in the moment. By telling ...
    (Date:1/22/2015)... A new white paper by The Beryl Institute ... long-term care environment as well as provides recommendations for ... “The Power of Person-Centeredness in Long-Term Care: A View ... patient, resident and family experience in long-term care and ...
    Breaking Medicine News(10 mins):Health News:Hastings and Hastings Reports a Record Number of Client Review Requests for Slip and Fall Accidents in 2014 2Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
    ... lower-tier facilities ,disappointing, , , THURSDAY, Jan. 31 (HealthDay News) ... United States have an average 27 percent lower risk ... the country, a new study shows. , Released Thursday ... of 27 procedures and diagnoses also found that patients ...
    ... February 29, 2008, PALO ALTO, Calif., Jan. ... announced today that the U.S. Food and,Drug Administration ... the,response by Solvay Pharmaceuticals, Inc. to the FDA ... Capsules. The,FDA has notified Solvay Pharmaceuticals that the ...
    ... Medarex, Inc.,(Nasdaq: MEDX ) announced today that it ... Biotechnology & Medical Device,Conference at 9:20 a.m. ET on ... and will be available in the Investor Relations section ... archived edition of the,presentation will be available following the ...
    ... Inc. (OTC Bulletin Board: ACPH) is pleased to ... Company,s application to,list its common stock on the ... commence trading on NASDAQ on February 4, 2008,under ... to join the growing list of specialty pharmaceutical,companies ...
    ... In hopes of gaining a better,grasp on the marketplace, ... sales training tools and techniques to,provide their sales representatives ... of training and preparation is critical for success, with,the ... $10,500 in,the first year of employment, more than double ...
    ... Essay Contest, TOMS RIVER, N.J., Jan. 31 ... "WORD About Health",Contest during a special luncheon at the ... enrolled in Toms River intermediate schools,to submit essays, poems ... and drug-free living. Over 1,900 students,submitted an entry in ...
    Cached Medicine News:Health News:Top-Rated Hospitals Continue to Deliver Better Care 2Health News:Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR 2Health News:Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference 2Health News:Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR 2Health News:Vital Training Tools Elevate New Pharmaceutical Sales Reps into Top Performers During Critical First Year 2Health News:AMERIGROUP Foundation Announces Winners of 'Word About Health' Contest 2
    Superior Skin Care...FlexWear skin barrier provides skin protection for an extended wear time....
    Firstchoice drainable pouch with softflex skin barrier, cushionfit backing, transparent odor-barrier quiet film and microporous adhesive....
    Inquire...
    ... Protects the skin over extended wearing ... barrier is the barrier of choice ... added benefit of it being discreet ... Security and confidence assured with internal ...
    Medicine Products: